Biochemical and pharmacological differences between preparations of exogenous natural surfactant used to treat Respiratory Distress Syndrome: Role of the different components in an efficient pulmonary surfactant

European Journal of Pharmacology

Volumn 568, Issue 1-3, 2007, Pages 1-15

  Blanco, Odalys ^a   Pérez Gil, Jesús ^b  

^a Direction of Animal Health and Production   (Cuba)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Air liquid interface; ARDS; Biochemical composition; Biophysics; Exogenous natural pulmonary surfactant; IRDS; Monolayer

Indexed keywords

BERACTANT; BLES; CALFACTANT; DIPALMITOYLPHOSPHATIDYLCHOLINE; LUNG SURFACTANT; LUNG SURFACTANT EXTRACT; LUSUPULTIDE; LYSOPHOSPHATIDYLCHOLINE; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLINOSITOL; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PORACTANT; PUMACTANT; SPHINGOMYELIN; SURFACEN; SURFACTANT PROTEIN A; SURFACTANT PROTEIN B; SURFACTANT PROTEIN C; SURFACTANT PROTEIN D; SURFACTANT TA; UNCLASSIFIED DRUG;

CHEMICAL COMPOSITION; CLINICAL TRIAL; DRUG EFFICACY; DRUG FORMULATION; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; LUNG ALVEOLUS; LUNG GAS EXCHANGE; LUNG LAVAGE; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; HUMANS; PEPTIDES; PULMONARY SURFACTANTS; RECOMBINANT PROTEINS; RESPIRATORY DISTRESS SYNDROME, ADULT;

EID: 34250832707     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.04.035     Document Type: Review

References (140)

1. Alonso C., Alig T., Yoon J., Bringezu F., Warriner H., and Zasadzinski J.A. More than a monolayer: relating lung surfactant structure and mechanics to composition. Biophys. J. 87 (2004) 4188-4202
2. Anzueto A., Baughman R.P., Guntupalli K.K., Weg J.G., Wiedemann H.P., Raventos A.A., Lemaire F., Long W., Zaccardelli D.S., and Pattishall E.N. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. Exosurf Acute Respiratory Distress Syndrome Sepsis Study Group. N. Engl. J. Med. 334 (1996) 1417-1421
3. Augusto L.A., Synguelakis M., Johansson J., Pedron T., Girard R., and Chaby R. Interaction of pulmonary surfactant protein C with CD14 and lipopolysaccharide. Infect. Immun. 71 (2003) 61-67
4. Bangham A.D., Morley C.J., and Phillips M.C. The physical properties of an effective lung surfactant. Biochim. Biophys. Acta 573 (1979) 552-556
5. Baroutis G., Kaleyias J., Liarou T., Papathoma E., Hatzistamatiou Z., and Costalos C. Comparison of three treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur. J. Pediatr. 162 (2003) 476-480
6. Bernardino de la Serna J., Perez-Gil J., Simonsen A.C., and Bagatolli L.A. Cholesterol rules: direct observation of the coexistence of two fluid phases in native pulmonary surfactant membranes at physiological temperatures. J. Biol. Chem. 279 (2004) 40715-40722
7. Bernhard W., Haagsman H.P., Tschernig T., Poets C.F., Postle A.D., van Eijk M.E., and von der Hardt H. Conductive airway surfactant: surface-tension function, biochemical composition, and possible alveolar origin. Am. J. Respir. Cell Mol. Biol. 17 (1997) 41-50
8. Bernhard W., Mottaghian J., Gebert A., Rau G.A., von Der H.H., and Poets C.F. Commercial versus native surfactants. Surface activity, molecular components, and the effect of calcium. Am. J. Respir. Crit. Care Med. 162 (2000) 1524-1533
9. Bi X., Flach C.R., Perez-Gil J., Plasencia I., Andreu D., Oliveira E., and Mendelsohn R. Secondary structure and lipid interactions of the N-terminal segment of pulmonary surfactant SP-C in Langmuir films: IR reflection-absorption spectroscopy and surface pressure studies. Biochemistry 41 (2002) 8385-8395
10. Blanco, O., 2006. Propiedades biofísicas, antiinflamatorias y antibacterianas de SURFACEN y su protección del daño oxidativo por la proteina SP-A. Ph. D. Thesis (University La Havana, La Havana, Cuba).
11. Blanco O., Riverón Y., de Armas E., Sánchez J., Faure R., and Fernández O. SURFACEN® inhibe el crecimiento de bacterias causantes de infecciones respiratorias. Biotecnol. Apl. 22 (2005) 279-281
12. Bloom B.T., Kattwinkel J., Hall R.T., Delmore P.M., Egan E.A., Trout J.R., Malloy M.H., Brown D.R., Holzman I.R., Coghill C.H., Carlo W.A., Pramanik A.K., McCaffree M.A., Toubas P.L., Laudert S., Gratny L.L., Weatherstone K.B., Seguin J.H., Willett L.D., Gutcher G.R., Mueller D.H., and Topper W.H. Comparison of Infasurf (calf lung surfactant extract) to Survanta (Beractant) in the treatment and prevention of respiratory distress syndrome. Pediatrics 100 (1997) 31-38
13. Bouhafs R.K., and Jarstrand C. Lipid peroxidation of lung surfactant by bacteria. Lung 177 (1999) 101-110
14. Cameron H.S., Somaschini M., Carrera P., Hamvas A., Whitsett J.A., Wert S.E., Deutsch G., and Nogee L.M. A common mutation in the surfactant protein C gene associated with lung disease. J. Pediatr. 146 (2005) 370-375
15. Casals C. Role of surfactant protein A (SP-A)/lipid interactions for SP-A functions in the lung. Pediatr. Pathol. Mol. Med. 20 (2001) 249-268
16. Clark H., and Reid K. The potential of recombinant surfactant protein D therapy to reduce inflammation in neonatal chronic lung disease, cystic fibrosis, and emphysema. Arch. Dis. Child. 88 (2003) 981-984
17. Clark J.C., Wert S.E., Bachurski C.J., Stahlman M.T., Stripp B.R., Weaver T.E., and Whitsett J.A. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7794-7798
18. Cockshutt A.M., Weitz J., and Possmayer F. Pulmonary surfactant-associated protein A enhances the surface activity of lipid extract surfactant and reverses inhibition by blood proteins in vitro. Biochemistry 29 (1990) 8424-8429
19. Cochrane C.G. A critical examination of the role of SP-B in alveolar expansion. Appl. Cardiopulm. Pathophysiol. 13 (2004) 27-29
20. Cochrane C.G., and Revak S.D. Pulmonary surfactant protein B (SP-B): structure-function relationships. Science 254 (1991) 566-568
21. Creuwels L.A., van Golde L.M., and Haagsman H.P. The pulmonary surfactant system: biochemical and clinical aspects. Lung 175 (1997) 1-39
22. Cruz A., Casals C., Plasencia I., Marsh D., and Perez-Gil J. Depth profiles of pulmonary surfactant protein B in phosphatidylcholine bilayers, studied by fluorescence and electron spin resonance spectroscopy. Biochemistry 37 (1998) 9488-9496
23. Cruz A., Worthman L.A., Serrano A.G., Casals C., Keough K.M., and Perez-Gil J. Microstructure and dynamic surface properties of surfactant protein SP-B/dipalmitoylphosphatidylcholine interfacial films spread from lipid-protein bilayers. Eur. Biophys. J. 29 (2000) 204-213
24. Cruz A., Vazquez L., Velez M., and Perez-Gil J. Effect of pulmonary surfactant protein SP-B on the micro- and nanostructure of phospholipid films. Biophys. J. 86 (2004) 308-320
25. Chaby R., Garcia-Verdugo I., Espinassous Q., and Augusto L.A. Interactions between LPS and lung surfactant proteins. J. Endotoxin Res. 11 (2005) 181-185
26. Daniels C.B., Barr H.A., Power J.H., and Nicholas T.E. Body temperature alters the lipid composition of pulmonary surfactant in the lizard Ctenophorus nuchalis. Exp. Lung Res. 16 (1990) 435-449
27. Ding J., Takamoto D.Y., von Nahmen A., Lipp M.M., Lee K.Y., Waring A.J., and Zasadzinski J.A. Effects of lung surfactant proteins, SP-B and SP-C, and palmitic acid on monolayer stability. Biophys. J. 80 (2001) 2262-2272
28. Discher B.M., Schief W.R., Vogel V., and Hall S.B. Phase separation in monolayers of pulmonary surfactant phospholipids at the air-water interface: composition and structure. Biophys. J. 77 (1999) 2051-2061
29. Epaud R., Ikegami M., Whitsett J.A., Jobe A.H., Weaver T.E., and Akinbi H.T. Surfactant protein B inhibits endotoxin-induced lung inflammation. Am. J. Respir. Cell Mol. Biol. 28 (2003) 373-378
30. Fujiwara T., Maeta H., Chida S., Morita T., Watabe Y., and Abe T. Artificial surfactant therapy in hyaline-membrane disease. Lancet 1 (1980) 55-59
31. Garcia-Verdugo I., Sanchez-Barbero F., Bosch F.U., Steinhilber W., and Casals C. Effect of hydroxylation and N187-linked glycosylation on molecular and functional properties of recombinant human surfactant protein A. Biochemistry 42 (2003) 9532-9542
32. Glasser S.W., Burhans M.S., Korfhagen T.R., Na C.L., Sly P.D., Ross G.F., Ikegami M., and Whitsett J.A. Altered stability of pulmonary surfactant in SP-C-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6366-6371
33. Glasser S.W., Detmer E.A., Ikegami M., Na C.L., Stahlman M.T., and Whitsett J.A. Pneumonitis and emphysema in sp-C gene targeted mice. J. Biol. Chem. 278 (2003) 14291-14298
34. Goerke J. Pulmonary surfactant: functions and molecular composition. Biochim. Biophys. Acta 1408 (1998) 79-89
35. Goerke J., and Clements J.A. Alveolar Surface Tension and Lung Surfactant (1986), American Physiological Society, Bethesda, MD 247-261
36. Gommers D., Vantveen A., Verbrugge S.J.C., and Lachmann B. Comparison of 8 different surfactant preparations on improvement of blood-gases in lung-lavaged rats. Appl. Cardiopulm. Pathophysiol. 7 (1998) 95-102
37. Gregory T.J., Steinberg K.P., Spragg R., Gadek J.E., Hyers T.M., Longmore W.J., Moxley M.A., Cai G.Z., Hite R.D., Smith R.M., Hudson L.D., Crim C., Newton P., Mitchell B.R., and Gold A.J. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 155 (1997) 1309-1315
38. Griese M. Pulmonary surfactant in health and human lung diseases: state of the art. Eur. Respir. J. 13 (1999) 1455-1476
39. Gunasekara L., Schurch S., Schoel W.M., Nag K., Leonenko Z., Haufs M., and Amrein M. Pulmonary surfactant function is abolished by an elevated proportion of cholesterol. Biochim. Biophys. Acta 1737 (2005) 27-35
40. Gunther A., Ruppert C., Schmidt R., Markart P., Grimminger F., Walmrath D., and Seeger W. Surfactant alteration and replacement in acute respiratory distress syndrome. Respir. Res. 2 (2001) 353-364
41. Gupta M., Hernandez-Juviel J.M., Waring A.J., Bruni R., and Walther F.J. Comparison of functional efficacy of surfactant protein B analogues in lavaged rats. Eur. Respir. J. 16 (2000) 1129-1133
42. Gustafsson M., Palmblad M., Curstedt T., Johansson J., and Schurch S. Palmitoylation of a pulmonary surfactant protein C analogue affects the surface associated lipid reservoir and film stability. Biochim. Biophys. Acta 1466 (2000) 169-178
43. Hawgood S., and Poulain F.R. The pulmonary collectins and surfactant metabolism. Annu. Rev. Physiol. 63 (2001) 495-519
44. Hawgood S., Ogawa A., Yukitake K., Schlueter M., Brown C., White T., Buckley D., Lesikar D., and Benson B. Lung function in premature rabbits treated with recombinant human surfactant protein-C. Am. J. Respir. Crit. Care Med. 154 (1996) 484-490
45. Holm B.A., Wang Z., Egan E.A., and Notter R.H. Content of dipalmitoyl phosphatidylcholine in lung surfactant: ramifications for surface activity. Pediatr. Res. 39 (1996) 805-811
46. Hudson L.D., and Steinberg K.P. Epidemiology of acute lung injury and ARDS. Chest 116 (1999) 74S-82S
47. Ikegami M., Whitsett J.A., Martis P.C., and Weaver T.E. Reversibility of lung inflammation caused by SP-B deficiency. Am. J. Physiol., Lung Cell. Mol. Physiol. 289 (2005) L962-L970
48. Ingenito E.P., Mora R., and Mark L. Pivotal role of anionic phospholipids in determining dynamic behavior of lung surfactant. Am. J. Respir. Crit. Care Med. 161 (2000) 831-838
49. Johansson J. Structure and properties of surfactant protein C. Biochim. Biophys. Acta 1408 (1998) 161-172
50. Kahn M.C., Anderson G.J., Anyan W.R., and Hall S.B. Phosphatidylcholine molecular species of calf lung surfactant. Am. J. Physiol. 269 (1995) L567-L573
51. Kaser M.R., and Skouteris G.G. Inhibition of bacterial growth by synthetic SP-B1-78 peptides. Peptides 18 (1997) 1441-1444
52. Kingma P.S., and Whitsett J.A. In defense of the lung: surfactant protein A and surfactant protein D. Curr. Opin. Pharmacol. 6 (2006) 277-283
53. Kishore U., Greenhough T.J., Waters P., Shrive A.K., Ghai R., Kamran M.F., Bernal A.L., Reid K.B., Madan T., and Chakraborty T. Surfactant proteins SP-A and SP-D: structure, function and receptors. Mol. Immunol. 43 (2006) 1293-1315
54. Knebel D., Sieber M., Reichelt R., Galla H.J., and Amrein M. Fluorescence light microscopy of pulmonary surfactant at the air-water interface of an air bubble of adjustable size. Biophys. J. 83 (2002) 547-555
55. Kramer A., Wintergalen A., Sieber M., Galla H.J., Amrein M., and Guckenberger R. Distribution of the surfactant-associated protein C within a lung surfactant model film investigated by near-field optical microscopy. Biophys. J. 78 (2000) 458-465
56. Lam B.C., Ng Y.K., and Wong K.Y. Randomized trial comparing two natural surfactants (Survanta vs. bLES) for treatment of neonatal respiratory distress syndrome. Pediatr. Pulmonol. 39 (2005) 64-69
57. Langman C., Orgeig S., and Daniels C.B. Alterations in composition and function of surfactant associated with torpor in Sminthopsis crassicaudata. Am. J. Physiol. 271 (1996) R437-R445
58. Lawson P.R., and Reid K.B. The roles of surfactant proteins A and D in innate immunity. Immunol. Rev. 173 (2000) 66-78
59. Lewis J.F., Goffin J., Yue P., McCaig L.A., Bjarneson D., and Veldhuizen R.A. Evaluation of exogenous surfactant treatment strategies in an adult model of acute lung injury. J. Appl. Physiol. 80 (1996) 1156-1164
60. Lewis J.F., and Veldhuizen R. The role of exogenous surfactant in the treatment of acute lung injury. Annu. Rev. Physiol. 65 (2003) 613-642
61. Lukovic D., Plasencia I., Taberner F.J., Salgado J., Calvete J.J., Perez-Gil J., and Mingarro I. Production and characterisation of recombinant forms of human pulmonary surfactant protein C (SP-C): Structure and surface activity. Biochim. Biophys. Acta 1758 (2006) 509-518
62. Manzanares D., Díaz E., Alfonso W., Escobar A., Colomé H., Muñoz M.C., Noa M., Rabell S., and Hidalgo A. Surfactante pulmonar porcino. Repúb. Cuba, A 61 K (1995) 35-42
63. Markart, P., Ruppert, C., Wygrecka, M., Colaris, T., Dahal, B., Walmrath, D., Harbach, H., Wilhelm, J., Seeger, W., Schmidt, R., Guenther, A., in press. Patients with ARDS show incomplete restoration of alveolar surface activity upon recombinant SP-C-based surfactant treatment: putative role of neutral lipids. Thorax. doi:thx.2006.062398v1.
64. Maruscak A., and Lewis J.F. Exogenous surfactant therapy for ARDS. Expert Opin. Investig. Drugs 15 (2006) 47-58
65. Mikawa K., Nishina K., Takao Y., and Obara H. Intratracheal application of recombinant surfactant protein-C surfactant to rabbits attenuates acute lung injury induced by intratracheal acidified infant formula. Anesth. Analg. 98 (2004) 1273-1279
66. Moen M.D., Perry C.M., and Wellington K. Lucinactant: in neonatal respiratory distress syndrome. Treat. Respir. Med. 4 (2005) 139-145 (discussion 146-137)
67. Morris R.H., Price A.J., Tonks A., Jackson S.K., and Jones K.P. Prostaglandin E(2) and tumour necrosis factor-alpha release by monocytes are modulated by phospholipids. Cytokine 12 (2000) 1717-1719
68. Nag K., Taneva S.G., Perez-Gil J., Cruz A., and Keough K.M. Combinations of fluorescently labeled pulmonary surfactant proteins SP-B and SP-C in phospholipid films. Biophys. J. 72 (1997) 2638-2650
69. Nag K., Munro J.G., Inchley K., Schurch S., Petersen N.O., and Possmayer F. SP-B refining of pulmonary surfactant phospholipid films. Am. J. Physiol. 277 (1999) L1179-L1189
70. Nag K., Pao J.S., Harbottle R.R., Possmayer F., Petersen N.O., and Bagatolli L.A. Segregation of saturated chain lipids in pulmonary surfactant films and bilayers. Biophys. J. 82 (2002) 2041-2051
71. Neumeister B., Woerndle S., and Bartmann P. Effects of different surfactant preparations on bacterial growth in vitro. Biol. Neonate 70 (1996) 128-134
72. Nogee L.M. Alterations in SP-B and SP-C expression in neonatal lung disease. Annu. Rev. Physiol. 66 (2004) 601-623
73. Notter R.H. Lung Surfactant: Basic Science and Clinical Applications (2000), Marcel Dekker, Inc., New York
74. Notter R.H., Tabak S.A., and Mavis R.D. Surface properties of binary mixtures of some pulmonary surfactant components. J. Lipid Res. 21 (1980) 10-22
75. Notter R.H., Egan E.A., Kwong M.S., Holm B.A., and Shapiro D.L. Lung surfactant replacement in premature lambs with extracted lipids from bovine lung lavage: effects of dose, dispersion technique, and gestational age. Pediatr. Res. 19 (1985) 569-577
76. Notter R.H., Wang Z., Egan E.A., and Holm B.A. Component-specific surface and physiological activity in bovine-derived lung surfactants. Chem. Phys. Lipids 114 (2002) 21-34
77. Oosterlaken-Dijksterhuis M.A., Haagsman H.P., van Golde L.M., and Demel R.A. Characterization of lipid insertion into monomolecular layers mediated by lung surfactant proteins SP-B and SP-C. Biochemistry 30 (1991) 10965-10971
78. Palmer D., Cheng S., Green F.Y., and Schurch S. The role of cholesterol in surfactant. Am. J. Respir. Crit. Care Med. 155 (1997) A214
79. Perez-Gil J. Molecular interactions in pulmonary surfactant films. Biol. Neonate 81 Suppl 1 (2002) 6-15
80. Perez-Gil J., and Keough K.M. Interfacial properties of surfactant proteins. Biochim. Biophys. Acta 1408 (1998) 203-217
81. Perez-Gil J., Tucker J., Simatos G., and Keough K.M. Interfacial adsorption of simple lipid mixtures combined with hydrophobic surfactant protein from pig lung. Biochem. Cell. Biol. 70 (1992) 332-338
82. Perez-Gil J., Casals C., and Marsh D. Interactions of hydrophobic lung surfactant proteins SP-B and SP-C with dipalmitoylphosphatidylcholine and dipalmitoylphosphatidylglycerol bilayers studied by electron spin resonance spectroscopy. Biochemistry 34 (1995) 3964-3971
83. Perkins W.R., Dause R.B., Parente R.A., Minchey S.R., Neuman K.C., Gruner S.M., Taraschi T.F., and Janoff A.S. Role of lipid polymorphism in pulmonary surfactant. Science 273 (1996) 330-332
84. Piknova B., Schief W.R., Vogel V., Discher B.M., and Hall S.B. Discrepancy between phase behavior of lung surfactant phospholipids and the classical model of surfactant function. Biophys. J. 81 (2001) 2172-2180
85. Plasencia I., Rivas L., Keough K.M., Marsh D., and Perez-Gil J. The N-terminal segment of pulmonary surfactant lipopeptide SP-C has intrinsic propensity to interact with and perturb phospholipid bilayers. Biochem. J. 377 (2004) 183-193
86. Plasencia I., Keough K.M., and Perez-Gil J. Interaction of the N-terminal segment of pulmonary surfactant protein SP-C with interfacial phospholipid films. Biochim. Biophys. Acta 1713 (2005) 118-128
87. Poets C.F., Arning A., Bernhard W., Acevedo C., and von der Hardt H. Active surfactant in pharyngeal aspirates of term neonates: lipid biochemistry and surface tension function. Eur. J. Clin. Invest. 27 (1997) 293-298
88. Possmayer F. A proposed nomenclature for pulmonary surfactant-associated proteins. Am. Rev. Respir. Dis. 138 (1988) 990-998
89. Possmayer F. Biophysical Activities of Pulmonary Surfactant in Fetal and Neonatal Physiology (1991), WB Saunders Co, Philadelphia 949-962
90. Poulain F.R., Allen L., Williams M.C., Hamilton R.L., and Hawgood S. Effects of surfactant apolipoproteins on liposome structure: implications for tubular myelin formation. Am. J. Physiol. 262 (1992) L730-L739
91. Ramanathan R., Rasmussen M.R., Gerstmann D.R., Finer N., and Sekar K. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am. J. Perinatol. 21 (2004) 109-119
92. Rauprich P., Moller O., Walter G., Herting E., and Robertson B. Influence of modified natural or synthetic surfactant preparations on growth of bacteria causing infections in the neonatal period. Clin. Diagn. Lab. Immunol. 7 (2000) 817-822
93. Revak S.D., Merritt T.A., Cochrane C.G., Heldt G.P., Alberts M.S., Anderson D.W., and Kheiter A. Efficacy of synthetic peptide-containing surfactant in the treatment of respiratory distress syndrome in preterm infant rhesus monkeys. Pediatr. Res. 39 (1996) 715-724
94. Robertson B., and Taeusch H. Surfactant therapy for lung disease (Lung biology in health and disease) (1995), Marcel Dekker, New York
95. Robertson B., and Halliday H.L. Principles of surfactant replacement. Biochim. Biophys. Acta 1408 (1998) 346-361
96. Robertson B., Curstedt T., Grossmann G., Kobayashi T., Kokubo M., and Suzuki Y. Prolonged ventilation of the premature newborn rabbit after treatment with natural or apoprotein-based artificial surfactant. Eur. J. Pediatr. 147 (1988) 168-173
97. Rodriguez Capote K., McCormack F.X., and Possmayer F. Pulmonary surfactant protein-A (SP-A) restores the surface properties of surfactant after oxidation by a mechanism that requires the Cys6 interchain disulfide bond and the phospholipid binding domain. J. Biol. Chem. 278 (2003) 20461-20474
98. Ross, A., 1999. Survanta (Beractant).
99. Ross M., Krol S., Janshoff A., and Galla H.J. Kinetics of phospholipid insertion into monolayers containing the lung surfactant proteins SP-B or SP-C. Eur. Biophys. J. 31 (2002) 52-61
100. Rosseau S., Hammerl P., Maus U., Gunther A., Seeger W., Grimminger F., and Lohmeyer J. Surfactant protein A down-regulates proinflammatory cytokine production evoked by Candida albicans in human alveolar macrophages and monocytes. J. Immunol. 163 (1999) 4495-4502
101. Rudiger M., Tolle A., Meier W., and Rustow B. Naturally derived commercial surfactants differ in composition of surfactant lipids and in surface viscosity. Am. J. Physiol., Lung Cell. Mol. Physiol. 288 (2005) L379-L383
102. Rustow B., Kolleck I., Guthmann F., Haupt R., Kunze D., and Stevens P. Synthesis and secretion of plasmalogens by type-II pneumocytes. Biochem. J. 302 Pt 3 (1994) 665-668
103. Ryan M.A., Akinbi H.T., Serrano A.G., Perez-Gil J., Wu H., McCormack F.X., and Weaver T.E. Antimicrobial activity of native and synthetic surfactant protein B peptides. J. Immunol. 176 (2006) 416-425
104. Sano H., Kuronuma K., Kudo K., Mitsuzawa H., Sato M., Murakami S., and Kuroki Y. Regulation of inflammation and bacterial clearance by lung collectins. Respirology 11 (2006) S46-S50 (Suppl)
105. Scarpelli E.M. Physiology of the alveolar surface network. Comp. Biochem. Physiol., Part A Mol. Integr. Physiol. 135 (2003) 39-104
106. Schoel W.M., Schurch S., and Goerke J. The captive bubble method for the evaluation of pulmonary surfactant: surface tension, area, and volume calculations. Biochim. Biophys. Acta 1200 (1994) 281-290
107. Schram V., and Hall S.B. Thermodynamic effects of the hydrophobic surfactant proteins on the early adsorption of pulmonary surfactant. Biophys. J. 81 (2001) 1536-1546
108. Schurch S., Possmayer F., Cheng S., and Cockshutt A.M. Pulmonary SP-A enhances adsorption and appears to induce surface sorting of lipid extract surfactant. Am. J. Physiol. 263 (1992) L210-L218
109. Schurch S., Qanbar R., Bachofen H., and Possmayer F. The surface-associated surfactant reservoir in the alveolar lining. Biol. Neonate 67 Suppl 1 (1995) 61-76
110. Schurch S., Bachofen H., and Possmayer F. Surface activity in situ, in vivo, and in the captive bubble surfactometer. Comp. Biochem. Physiol., Part A Mol. Integr. Physiol. 129 (2001) 195-207
111. Seeger W., Grube C., Gunther A., and Schmidt R. Surfactant inhibition by plasma proteins: differential sensitivity of various surfactant preparations. Eur. Respir. J. 6 (1993) 971-977
112. Serrano A.G., and Perez-Gil J. Protein-lipid interactions and surface activity in the pulmonary surfactant system. Chem. Phys. Lipids 141 (2006) 105-118
113. Serrano A.G., Cabre E.J., Oviedo J.M., Cruz A., Gonzalez B., Palacios A., Estrada P., and Perez-Gil J. Production in Escherichia coli of a recombinant C-terminal truncated precursor of surfactant protein B (rproSP-B Delta C). Structure and interaction with lipid interfaces. Biochim. Biophys. Acta 1758 (2006) 1621-1632
114. Shapiro D.L., and Notter R.H. Surfactant Replacement Therapy (1989), John Wiley & Sons Inc, New York
115. Shapiro D.L., Notter R.H., Morin III F.C., Deluga K.S., Golub L.M., Sinkin R.A., Weiss K.I., and Cox C. Double-blind, randomized trial of a calf lung surfactant extract administered at birth to very premature infants for prevention of respiratory distress syndrome. Pediatrics 76 (1985) 593-599
116. Shelley S.A., Paciga J.E., and Balis J.U. Lung surfactant phospholipids in different animal species. Lipids 19 (1984) 857-862
117. Sinha S.K., Lacaze-Masmonteil T., Valls i Soler A., Wiswell T.E., Gadzinowski J., Hajdu J., Bernstein G., Sanchez-Luna M., Segal R., Schaber C.J., Massaro J., and d'Agostino R. A multicenter, randomized, controlled trial of lucinactant versus poractant alfa among very premature infants at high risk for respiratory distress syndrome. Pediatrics 115 (2005) 1030-1038
118. Speer C.P., Gefeller O., Groneck P., Laufkotter E., Roll C., Hanssler L., Harms K., Herting E., Boenisch H., Windeler J., et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch. Dis. Child., Fetal Neonatal Ed. 72 (1995) F8-F13
119. Spragg R.G., Gilliard N., Richman P., Smith R.M., Hite R.D., Pappert D., Robertson B., Curstedt T., and Strayer D. Acute effects of a single dose of porcine surfactant on patients with the adult respiratory distress syndrome. Chest 105 (1994) 195-202
120. Spragg R.G., Lewis J.F., Wurst W., Hafner D., Baughman R.P., Wewers M.D., and Marsh J.J. Treatment of acute respiratory distress syndrome with recombinant surfactant protein C surfactant. Am. J. Respir. Crit. Care Med. 167 (2003) 1562-1566
121. Spragg R.G., Lewis J.F., Walmrath H.D., Johannigman J., Bellingan G., Laterre P.F., Witte M.C., Richards G.A., Rippin G., Rathgeb F., Hafner D., Taut F.J., and Seeger W. Effect of recombinant surfactant protein C-based surfactant on the acute respiratory distress syndrome. N. Engl. J. Med. 351 (2004) 884-892
122. Taeusch H.W., Lu K., and Ramirez-Schrempp D. Improving pulmonary surfactants. Acta Pharmacol. Sin. 23 (2002) 11-15
123. Takamoto D.Y., Lipp M.M., von Nahmen A., Lee K.Y., Waring A.J., and Zasadzinski J.A. Interaction of lung surfactant proteins with anionic phospholipids. Biophys. J. 81 (2001) 153-169
124. Taneva S., and Keough K.M. Pulmonary surfactant proteins SP-B and SP-C in spread monolayers at the air-water interface: III. Proteins SP-B plus SP-C with phospholipids in spread monolayers. Biophys. J. 66 (1994) 1158-1166
125. Taneva S., and Keough K.M. Cholesterol modifies the properties of surface films of dipalmitoylphosphatidylcholine plus pulmonary surfactant-associated protein B or C spread or adsorbed at the air-water interface. Biochemistry 36 (1997) 912-922
126. Tonks A., Morris R.H., Price A.J., Thomas A.W., Jones K.P., and Jackson S.K. Dipalmitoylphosphatidylcholine modulates inflammatory functions of monocytic cells independently of mitogen activated protein kinases. Clin. Exp. Immunol. 124 (2001) 86-94
127. Tonks A.J., Tonks A., Morris R.H., Jones K.P., and Jackson S.K. Regulation of platelet-activating factor synthesis in human monocytes by dipalmitoyl phosphatidylcholine. J. Leukoc. Biol. 74 (2003) 95-101
128. Tonks A., Parton J., Tonks A.J., Morris R.H., Finall A., Jones K.P., and Jackson S.K. Surfactant phospholipid DPPC downregulates monocyte respiratory burst via modulation of PKC. Am. J. Physiol., Lung Cell. Mol. Physiol. 288 (2005) L1070-L1080
129. Vandenbussche G., Clercx A., Clercx M., Curstedt T., Johansson J., Jornvall H., and Ruysschaert J.M. Secondary structure and orientation of the surfactant protein SP-B in a lipid environment. A Fourier transform infrared spectroscopy study. Biochemistry 31 (1992) 9169-9176
130. Veldhuizen R., Nag K., Orgeig S., and Possmayer F. The role of lipids in pulmonary surfactant. Biochim. Biophys. Acta 1408 (1998) 90-108
131. Waring A.J., Walther F.J., Gordon L.M., Hernandez-Juviel J.M., Hong T., Sherman M.A., Alonso C., Alig T., Braun A., Bacon D., and Zasadzinski J.A. The role of charged amphipathic helices in the structure and function of surfactant protein B. J. Pept. Res. 66 (2005) 364-374
132. Wauer R., Rogalski M., Schwerecke A., and Schmalisch G. Prophylaxe and Therapie des neonatalen atemnotsyndroms durch endotracheale application exogen en surfactants-eine literaturbersicht. Klin. Med. 46 (1991) 985-992
133. Wauer R. Respiratory distress syndrome. In: Wauer R.R. (Ed). Surfactant therapy: basic principles, diagnosis, therapy (1998), Thieme Medical Publication, Stuttgart, Germany 2-19
134. Wright J.R. Immunomodulatory functions of surfactant. Physiol. Rev. 77 (1997) 931-962
135. Wright J.R. Pulmonary surfactant: a front line of lung host defense. J. Clin. Invest. 111 (2003) 1453-1455
136. Wright J.R. Immunoregulatory functions of surfactant proteins. Nat. Rev., Immunol. 5 (2005) 58-68
137. Wustneck R., Perez-Gil J., Wustneck N., Cruz A., Fainerman V.B., and Pison U. Interfacial properties of pulmonary surfactant layers. Adv. Colloid Interface Sci. 117 (2005) 33-58
138. Yeagle P.L., and Sen A. Hydration and the lamellar to hexagonal II phase transition of phosphatidylethanolamine. Biochemistry 25 (1986) 7518-7522
139. Yu S., Harding P.G., Smith N., and Possmayer F. Bovine pulmonary surfactant: chemical composition and physical properties. Lipids 18 (1983) 522-529
140. Zhang J.P., Wang Y.L., Wang Y.H., Zhang R., Chen H., and Su H.B. Prophylaxis of neonatal respiratory distress syndrome by intra-amniotic administration of pulmonary surfactant. Chin. Med. J. (Engl.) 117 (2004) 120-124